

MEMO

To:	Network Pharmacy
From:	Elixir
Date:	Thursday, December 17, 2020
RE:	COVID-19 Vaccine Claim Processing

Dear Pharmacy:

On December 11, 2020, the U.S. Food and Drug Administration issued an emergency use authorization allowing the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S. Authorization of additional COVID vaccines may come in the near future as well. Please review the information below regarding the COVID-19 Vaccine coverage, reimbursement, and billing.

- For pharmacies enrolled with the Federal COVID-19 Vaccination Program, you may begin processing the COVID-19 Vaccine effective today, as supply is available.
- Elixir will support the adjudication of the COVID-19 Vaccine for commercial and Medicaid clients (if applicable). For beneficiaries enrolled in Medicare Advantage plans during CY 2020 and 2021, payment for the COVID-19 Vaccine and its administration will be made through the original fee-for-service Medicare program. The reject messaging for Medicare Part D BIN/PCN (PDP or MAPD) will be A5 (Not Covered under Part D law) with additional messaging to bill Medicare Part B FFS.
- The vaccine itself will be paid for through funding authorized by the Coronavirus Aid, Relief, and Economic Security (CARES) Act, but administration of the vaccine by pharmacies will be paid for by the payer (for example, the private insurance company, Medicare FFS, or the Provider Relief Fund)
- Elixir will reimburse pharmacies an administration fee for the COVID-19 Vaccine when administered to members. Single dose vaccines will receive an administration fee of \$28.39. Multi-dose vaccines will receive an administration fee of \$16.94 for the initial dose and \$28.39 for the second dose.
 - The <u>correct administration fee</u> must be entered in the "Incentive Amount Submitted" field which appears as FIELD #438-E3 on the Payer Sheet.
- Two-dose vaccines must be submitted with the NCPDP identified Submission Clarification Codes to differentiate between the first and second dose. For the first of two doses, Pharmacy must submit the Submission Clarification Code of 2 "Other Override". For the second and final dose, Pharmacy must submit the Submission Clarification Code of 6 "Starter Dose".
 - The correct Submission Clarification Code (SCC) <u>must be entered</u> in the "Submission Clarification Code" field which appears as FIELD #420-DK on the Payer Sheet.
- As with all vaccine claim submissions, <u>pharmacies must submit</u> "MA" in the "Professional Service Code" field which appears as FIELD #440-E5 on the Payer Sheet.

Privacy & Confidentiality of Information Notice: This communication may contain non-public, confidential, or legally privileged information intended for the sole use of the designated recipients. If you are not the intended recipient, or have received this communication in error, please notify the sender immediately by reply email or by telephone at 800.361.4542, and delete all copies of this communication, including attachments, without reading them or saving them to disk. If you are the intended recipient, you must secure the contents in accordance with all applicable state or federal requirements related to the privacy and confidentiality of information, including the HIPAA Privacy guidelines.

IF YOU DO NOT WISH TO RECEIVE EMAILS from an Elixir company you may send a request to us via fax to 866.250.5178 (toll free) or via email to care@elixirsolutions.com (must state "Email Opt Out" in the subject line) or call 800.361.4542 (toll free) instructing us not to send you further emails. Your request will be deemed valid only if: (1) it contains the address(es) of the email(s) that should not receive an email from us; and (2) you do not subsequently give us permission to send emails to the previously provided email address. You must request that we resume emails to you by contacting us at the telephone number, fax number, or email address listed above. Federal law requires us to comply with your request within 30 days.

- For additional guidance on accurate claims submission, please review the "NCPDP Emergency Preparedness Guidance COVID-19 Vaccines" (<u>https://www.ncpdp.org/NCPDP/media/pdf/NCPDP-Emergency-Preparedness-Guidance-COVID-19-Vaccines.pdf</u>).
- Members will NOT have any cost share amount and should not be charged anything out of pocket.
- The list of covered GPIs will be listed in the Pharmacy Manual and updated as new GPIs become available. We are not
 requiring that pharmacies sign an amendment as the Pharmacy Manual will outline administration fee reimbursement. The
 Pharmacy Manual can be found at https://www.elixirsolutions.com/providers under the "Processing Information" category.

Thank you,

Elixir